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Background: Glutathione S-transferases (GSTs) have proved to be involved in the detoxifying several carcinogens
and may play an important role in carcinogenesis of cancer. Previous studies on the association between Glutathione
S-transferase M1 (GSTM1) polymorphism and gastric cancer (GC) risk reported inconclusive results. To get a precise
result, we conducted this present meta-analysis through pooling all eligible studies.
Methods: A comprehensive databases of Pubmed, Embase, Web of Science, and the Chinese Biomedical Database
(CBM) were searched for case–control studies investigating the association between GSTM1 null genotype and GC risk.
Odds ratios (OR) and 95% confidence intervals (95% CI) were used to assess this possible association. A χ2-based Q-test
was used to examine the heterogeneity assumption. Begg’s and Egger’s test were used to examine the potential
publication bias. The leave-one-out sensitivity analysis was conducted to determine whether our assumptions or
decisions have a major effect on the results of present work. Statistical analyses were performed with the software
program STATA 12.0.
Results: A total of 47 eligible case–control studies were identified, including 6,678 cases and 12,912 controls. Our
analyses suggested that GSTM1 null genotype was significantly associated with increased risk of GC (OR = 1.186,
95% CI = 1.057-1.329, Pheterogenetiy = 0.000, P = 0.004). Significant association was also found in Asians (OR = 1.269,
95% CI = 1.106-1.455, Pheterogenetiy = 0.002, P = 0.001). However, GSTM1 null genotype was not contributed to GC risk in
Caucasians (OR = 1.115, 95% CI = 0.937-1.326, Pheterogenetiy = 0.000, P = 0.222). In the subgroup analysis stratified by
sources of controls, significant association was detected in hospital-based studies (OR = 1.355, 95% CI = 1.179-1.557,
Pheterogenetiy = 0.001, P = 0.000), while there was no significant association detected in population-based studies
(OR = 1.017, 95% CI = 0.862-1.200, Pheterogenetiy = 0.000, P = 0.840).
Conclusion: This meta-analysis showed the evidence that GSTM1 null genotype contributed to the development of GC.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1644180505119533.
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Multiple lines of evidence suggested both cumulative ef-
fect of environmental risk factors and genetic suscepti-
bility of the individual contributed to the development
of the cancers [1]. The gene-environment interaction in
carcinogenesis is also well reflected by metabolic en-
zymes involved in the inactivation and/or detoxification
of environmental carcinogens. Most of the carcinogens* Correspondence: yongliu_sy@126.com
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unless otherwise stated.are metabolically inactivated by detoxification enzymes.
Therefore, inherited variations in genes encoding the
carcinogen-metabolizing enzymes may alter enzymatic
activity and subsequently the carcinogens activation
and/or deactivation [2]. Individual susceptibility to can-
cer is likely to be affected by the genotypes of biotrans-
formation enzymes which represent significant ethnic
differences in the frequency of alleles [3].
Human glutathione S-transferases (GSTs) are phase II
metabolizing enzymes that play a key role in protecting
against cancer by detoxifying numerous potentially cyto-
toxic/genotoxic compounds [4]. The genes encoding thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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1, and GSTP (pi) 1, widely expressed along the human
gastrointestinal tract [5], are highly polymorphic. Among
the GST isoforms, glutathione S-transferase M1 (GSTM1)
is of particular interest and important because it possesses
a present/null polymorphism and the null genotype has a
complete absence of GSTM1 enzyme activity. It has been
observed that GSTM1 null may affect individual suscepti-
bility to cancer [6]. Up to now, numerous researches about
the relationship between the polymorphism of GSTM1
null genotype and GC susceptibility have been conducted.
However, the findings are controversial due to different
reasons including the populations selected and their eth-
nicities. A recent meta-analysis of 15 studies suggested no
association between the GSTM1 polymorphism and GC
susceptibility was found [7]. When they performed the
meta-analysis, the pooled sample size was relatively small
and not enough information was available for more ex-
haustive subgroup analysis. Since then, additional several
studies with a large sample size about this polymorphism
on GC risk have been reported, which would greatly
improve the power of the meta-analysis. In order to
get a more precise result, we conducted this present
meta-analysis.
Methods
Search strategy for eligible studies
We conducted a comprehensive search through the Pubmed,
Embase, Web of Science, and Chinese Biomedical Data-
base (CBM) databases for studies assessing the association
between GSTM1 null genotype and GC risk. The litera-
ture strategy used the following keywords: (“Glutathione
S-transferase M1”, “GSTM1” or “GSTM”) and (“gastric
cancer”, “gastric carcinoma”, “stomach cancer” or “stom-
ach carcinoma”). There was no sample size and language
limitation. We evaluated all associated publications to
retrieve the most eligible literatures. All references
cited in the included studies were also hand-searched
and reviewed to identify additional published articles
not indexed in common databases. Of the studies with
overlapping data published by the same authors, only the
most recent or complete study was included in this
meta-analysis.
Inclusion and exclusion criteria
The inclusion criteria of eligible studies were as follow-
ing: (1) Evaluate the GSTM1 polymorphism and GC
risk; (2) Only the case–control studies were considered;
(3) The paper should clearly describe the diagnoses of
GC and the sources of cases and controls; (4) The con-
trols were gastric cancer-free individuals; (5) Reported
the frequencies of GSTM1 polymorphism in both cases
and controls or the odds ratio (OR) and its 95% confi-
dence interval (95% CI) of the association between GSTM1null genotype and GC risk. The exclusion criteria
were: (1) none case–control studies; (2) control population
including malignant tumor patients; and (3) duplicated
publications.
Data extraction
Relevant data were extracted from all the eligible studies
independently by two reviewers, and disagreements were
settled by discussion and the consensus was reached
among all reviewers. The main data extracted from the
eligible studies were as following: the first author, year of
publication, ethnicity, genotype method, source of the
controls, total numbers of cases and controls, the geno-
type frequency of GSTM1 polymorphism. Different eth-
nicities were mainly categorized as Caucasians, Asians,
Africans, and Mixed. If a study did not specify the ethni-
city or if it was not possible to separate participants ac-
cording to such phenotype, the group was termed
“mixed”. For studies including subjects of different eth-
nic populations, data were collected separately whenever
possible and recognized as an independent study.
Quality assessment
Quality of eligible studies in present meta-analysis was
assessed using the Newcastle Ottawa scale (NOS) as rec-
ommended by the Cochrane Non-Randomized Studies
Methods Working Group. This instrument was devel-
oped to assess the quality of non-randomized studies,
specifically cohort and case–control studies [8]. This in-
strument was developed to assess the quality of nonran-
domized studies, specifically cohort and case–control
studies. Based on the NOS, case–control studies were
judged based on three broad perspectives: selection of
study groups (1 criterion), comparability of study groups
(4 criteria), and ascertainment of outcome of interest (3
criteria). Given the variability in quality of observational
studies found on our initial literature search, we consid-




We examined the association between GSTM1 null
genotype and GC risk by calculating pooled odds ratio
(ORs), 95% confidence intervals (95% CI), and the sig-
nificance of the pooled OR was determined by the Z-
test. To assess the heterogeneity among the included
studies more precisely, both the chi-square based Q stat-
istic test (Cochran’s Q statistic) to test for heterogeneity
and the I2 statistic to quantify the proportion of the total
variation due to heterogeneity [10,11]. If obvious hetero-
geneity existed among those included studies (P < 0.05),
the random-effect model (DerSimonian and Laird method)
was used to pool the results [12]. When there was no
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ies (P > 0.05), the fixed-effect model (Mantel-Haenszel’s
method) was used to pool the results [13]. Moreover, sub-
group analyses were performed to test whether the effect
size varied by the ethnicity and the source of control
population. The kinds of ethnicity were mainly defined as
Caucasians, Asians. Publication bias was investigated with
the funnel plot and its asymmetry suggested risk of publi-
cation bias. To evaluate the published bias, we used Begg’s
[14] and Egger’s [15] formal statistical test and by visual
inspection of the funnel plot. Furthermore, the leave-
one-out sensitivity analysis was conducted to deter-
mine whether our assumptions or decisions have a
major effect on the results of the review by omitting
each study [16]. All statistical tests for this meta-
analysis were performed with STATA (version 12.0; Stata
Corporation, College Station, TX). A P value less than
0.05 was considered statistically significant, and all the
P values were two sided.
Results
Study characteristics
There were 113 relevant abstracts identified by searching
the key words, and 41 studies were firstly excluded afterFigure 1 Flow chart of study selection.the careful review of the abstracts, leaving 72 studies for
full publication review (Figure 1). Of those 72 studies, 25
studies were excluded (6 for containing overlapping data,
11 for reviews, 3 for without adequate data, and 5 for on
GSTT1 polymorphism). Table 1 listed the main charac-
teristics of eligible studies included in this meta-analysis.
There are 47 case–control studies, including 6,678 cases
and 12,912 controls met the selection criteria [2,17-62].
Among the 47 studies, 24 studies are of Caucasians and
23 studies are of Asians. There are 25 studies of hospital-
based controls and the rest are population-based controls.
Quantitative synthesis
Overall, there was significant association between GC
risk and the GSTM1 null genotypes when all the eligible
studies were pooled into the meta-analysis (OR = 1.186,
95% CI = 1.057-1.329, Pheterogenetiy = 0.000, P = 0.004,
Figure 2). Simultaneously, significant association was
also found in Asians (OR = 1.269, 95% CI = 1.106-
1.455, Pheterogenetiy = 0.002, P = 0.001, Figure 3). How-
ever, GSTM1 null genotype was not increased the risk
of GC in Caucasians (OR = 1.115, 95% CI = 0.937-1.326,
Pheterogenetiy = 0.000, P = 0.222, Figure 3). In the subgroup
analysis stratified by sources of controls, significant
Table 1 Main characteristics of all the eligible studies in this meta-analysis
First author Year Ethnicity Control source Sample size Case Control
Case Control Present Null Present Null
Strange et al. 1991 Caucasian Hospital-based 19 49 5 14 29 20
Harada et al. 1992 Asian Population-based 19 84 14 5 44 40
Kato et al. 1996 Asian Hospital-based 64 120 34 30 59 61
Katoh et al. 1996 Asian Population-based 139 126 60 79 71 55
Deakin et al. 1996 Caucasian Hospital-based 136 577 64 72 261 316
Enders et al. 1998 Caucasian Hospital-based 51 35 23 28 22 13
Martins et al. 1998 Caucasian Hospital-based 148 84 77 71 40 44
Oda et al. 1999 Asian Hospital-based 147 112 56 91 57 55
Cai et al. 1999 Asian Population-based 95 94 35 60 51 43
Setiawan et al. 2000 Asian Population-based 87 419 45 42 207 212
Lan et al. 2001 Caucasian Population-based 347 426 180 167 204 222
Saadat et al. 2001 Caucasian Population-based 42 131 16 26 78 53
Gao et al. 2002 Asian Population-based 153 223 63 90 90 133
Wu et al. 2002 Asian Hospital-based 356 278 183 173 142 136
Sgambato et al. 2002 Caucasian Hospital-based 8 100 3 5 47 53
Choi et al. 2003 Asian Population-based 80 177 34 46 82 95
Roth et al. 2004 Asian Population-based 90 454 66 24 309 145
Suzuki et al. 2004 Asian Hospital-based 145 177 58 87 93 84
Colombo et al. 2004 Mixed Population-based 100 150 53 47 88 62
Lai et al. 2005 Asian Hospital-based 123 121 50 73 66 55
Li et al. 2005 Asian Hospital-based 100 62 33 67 36 26
Mu et al. 2005 Asian Population-based 196 393 69 127 158 235
Nan et al. 2005 Asian Hospital-based 400 614 149 251 254 360
Shen et al. 2005 Asian Hospital-based 142 675 41 71 314 361
Palli et al. 2005 Caucasian Population-based 175 546 85 90 271 275
Tamer et al. 2005 Caucasian Hospital-based 70 204 30 40 116 88
Nan et al. 2005 Asian Hospital-based 107 220 34 73 90 130
Hong et al. 2006 Asian Hospital-based 108 238 48 60 104 134
Agudo et al. 2006 Caucasian Population-based 242 927 120 122 434 498
Martinez et al. 2006 Caucasian Population-based 87 329 54 33 180 149
Boccia et al. 2007 Caucasian Hospital-based 105 256 48 59 119 135
Ruzzo et al. 2007 Caucasian Population-based 79 112 44 35 51 61
Wideroff et al. 2007 Caucasian Population-based 116 209 55 61 87 121
Tripathi et al. 2008 Caucasian Population-based 76 100 45 31 61 39
Al-Moundhri et al. 2009 Caucasian Population-based 107 107 65 42 75 32
Masoudi et al. 2009 Caucasian Hospital-based 67 134 30 37 74 60
Malik et al. 2009 Caucasian Hospital-based 108 195 44 64 116 79
Moy et al. 2009 Caucasian Population-based 170 735 72 98 320 415
Zendehdel et al. 2009 Caucasian Population-based 181 624 54 70 230 239
Palli et al. 2010 Caucasian Population-based 296 546 206 90 271 275
Yadav et al. 2010 Asian Hospital-based 133 270 84 49 150 120
Luo et al. 2010 Asian Hospital-based 123 129 30 93 58 71
Nguyen et al. 2010 Asian Hospital-based 59 109 16 43 34 75
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Table 1 Main characteristics of all the eligible studies in this meta-analysis (Continued)
Darazy et al. 2011 Caucasian Hospital-based 13 70 7 6 58 12
García-González et al. 2012 Caucasian Hospital-based 557 557 274 283 290 267
Malakar et al. 2012 Asian Population-based 102 204 45 57 107 97
Jing et al. 2012 Asian Hospital-based 410 410 170 240 203 207
Figure 2 Meta-analysis of the association between GSTT1 null genotype and gastric cancer risk.
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Figure 3 Subgroup analyses of the association between GSTT1 null genotype and gastric cancer risk by the ethnicity.
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Figure 4 Subgroup analyses of the association between GSTT1 null genotype and gastric cancer risk according to the source
of controls.
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Figure 5 Sensitive analysis of the pooled ORs and 95% CI for the overall analysis, omitting each dataset in the meta-analysis.
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1.355, 95% CI = 1.179-1.557, Pheterogenetiy = 0.001, P = 0.000,
Figure 4), while there was no significant association de-
tected in population-based studies (OR = 1.017, 95% CI =
0.862-1.200, Pheterogenetiy = 0.000, P = 0.840, Figure 4).
Sensitivity analysis
In order to compare the sensitivity of this meta-analysis,
we conducted a leave-one-out sensitivity analysis. A singleFigure 6 Begg’s test for detecting the potential publication bias.study involved in this meta-analysis was evaluated each
time to reflect the influence of the individual data set to
pooled ORs. The results pattern was not impacted by sin-
gle study (Figure 5).
Publication bias
Begg’s funnel plot and Egger’s test were used to assess
the publication bias in this present work. The Funnel
plots’ shape did not reveal obvious evidence of asymmetry
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0.05, providing statistical evidence for the funnel plots’
symmetry.
Discussion
Gastric cancer is one of the most common malignancies
in the world which accounts for 9.7% of total cancer
deaths. Multiple factors have been proved contributed to
the development of GC, including environmental, such
as, Helicobacter pylori infection, Tobacco smoking and
individual genetic polymorphism [63,64]. Since the first
publication in 1991 by Strange et al. [17] reporting the
association between the GSTT1 null genotype and the
increased risk of GC, a large number of epidemiological
studies concerning the link between GST gene polymor-
phisms and GC risk have been conducted. GSTM1 is
generally considered as a protective enzyme because it
detoxifies a number of toxic and carcinogenic substances
such as nitrosamines and PAHs including BPDE [65].
As we all known, meta-analysis has great power to give
a more credible results in one field than individual study
through analyzing all the published research works with
the same field [66,67]. Previous epidemiological studies
have evaluated the association between the GSTM1 poly-
morphism and GC risk, but with inconclusive results.
Therefore, it is necessary to perform this meta-analysis to
identify the association between GSTM1 polymorphism
and GC risk by combining the relevant studies published
to date. Detection of gene genotype in all kinds of cancer
not only in GC patient, which can be used for new thera-
peutic targets, will modify the current therapeutic ap-
proach. After pooling available data from all included
studies, we found that there was significant association be-
tween this polymorphism and GC risk in over the world
population. Our data are in line with those reported by
Saadat et al. [68] and Boccia et al. [69] who observed a sig-
nificantly increased risk of GC. This association can be ex-
plained by the reduced ability to detoxify the reactive
intermediates that react with DNA because of the lack of
GSTM1 enzyme activity [70].
It has been well known that cancer occurrence and
mortality varied by ethnicity and geographic location.
Piao et al. [71] suggested it was not associated with GC
risk in different populations. In present work, significant
association of GSTM1 polymorphism with GC risk was
detected in Asian populations. However, no association
was detected in Caucasians, which in line with previous
meta-analysis conducted by Qiu et al. [72]. When stratified
by source of controls, significant association between
GSTM1 polymorphism and GC risk was observed among
hospital-based studies. Many factors may contribute to this
result, incompleteness of search, and include the potential
false diagnoses (clinic, documentation, statistical methods).
Furthermore, the use of typical control populations isvitally important, especially for the genetic association
studies. The failure to reach a statistical significance in
population-based studies implies that the selection of rep-
resentative controls may reduce bias of the results.
Some limitations of this study should be acknowl-
edged. Firstly, there was some heterogeneity in both the
meta-analysis of total 48 studies and the subgroup ana-
lyses by ethnicity. The differences from the selection cri-
teria of cases or controls, the adjusted confounding
variables, and the ethnicity result in the heterogeneity.
Secondly, most studies in the meta-analysis were retro-
spective design which could suffer more risk of bias
owing to the methodological deficiency of retrospective
studies. Those there was no obvious risk of publication
bias in the present meta-analysis, the risks of other po-
tential bias were unable to be excluded. Some misclassi-
fication bias was possible because most studies could
not exclude latent gastric cancer cases in the control
group. Therefore, more studies with prospective design
and low risk of other bias are needed to provide a more
precise estimate of the association between GSTM1 null
genotype and GC risk. Finally, we could not address
gene-gene and gene-environmental interactions in the
association between GSTM1 null genotype and GC risk.
Conclusion
In conclusion, the meta-analysis with all the eligible stud-
ies published up to now, provides a more precise evidence
for the significant association between GSTM1 null geno-
type and increased risk of GC. In addition, more individ-
ual studies with well design are needed to further assess
the possible gene-gene and gene-environmental interac-
tions in the association between GSTM1 null genotype
and GC risk.
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